Eli Lilly Expands Investment in Indiana
Eli Lilly & Company has announced a substantial investment of $4.5 billion in Indiana, increasing its total investments in the state to over $21 billion since 2020.
This latest funding, which President Trump shared on Truth Social after a Wednesday press release, will bolster two sites in Lebanon: the Lilly Lebanon API facility, aimed at producing future active pharmaceutical ingredients, and Lilly Lebanon Advanced Therapies.
The latter, which opened its doors on Wednesday, is notable as the company’s first facility focused on producing genetic medicines.
Lilly has established Lebanon as a key element of its domestic manufacturing strategy. Back in 2024, plans were unveiled to produce its weight management and type 2 diabetes drugs, Zepbound and Mounjaro, at the Lebanon API facility.
This new investment expands on those initiatives with plans for manufacturing the weight loss drug Foundayo, along with letaltortide, which is in advanced development stages for addressing obesity and cardiometabolic issues, as noted by Lilly.
“The legacy of Indiana’s first Lilly continues today, and the best measure of that legacy is what we do next,” stated David Ricks, Lilly Chairman and CEO.
“From genetic medicines that may one day prevent disease at its source to Foundayo, a pill that will make weight loss treatment accessible to millions, we are not just discovering future medicines, we’re building the most advanced programs to create them,” he added.
Ricks also mentioned that the Lebanon API facility, set to open in 2027, will stand as the largest active pharmaceutical ingredient production site in U.S. history.
“This expansion showcases the strength of Lilly’s long-standing partnership with Indiana, which consistently delivers tangible results for Hoosiers,” remarked Gov. Mike Brown (R-Ind.).
In making a case for its pivotal role in the local economy, Lilly referenced an upcoming report from the Indiana University Kelley School of Business and the Indiana Business Research Center, estimating that the company contributes an astonishing 70% of Indiana’s pharmaceutical GDP.
Lilly attributed its growth to a conducive domestic policy environment, which has facilitated a broader national expansion beyond Indiana’s borders. This growth momentum is anticipated to persist through the year’s end, with plans for several new manufacturing sites across the U.S. to enhance its domestic supply chain.
“Lilly’s U.S. capital expansion commitments since 2020 exceed $50 billion, investments made possible thanks to policies that support domestic manufacturing,” the company stated in its release.
